Inactive Instrument

News Selectimmune Pharma AB (publ)

Equities

SELECT B

SE0012622785

Summary

Unlock all the news: Be the first to know and act before the market!

Selectimmune Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	23-08-29	CI
Selectimmune Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-25	CI
Hamlet BioPharma AB (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB.	23-05-16	CI
Hamlet Pharma & SelectImmune Pharma invites to a digital investor meeting on April 3rd and April 4th at 12.00 CET	23-03-31	AQ
Hamlet Pharma AB (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (NGM:SELECT B).	23-03-30	CI
Selectimmune Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-23	CI
Selectimmune Pharma AB Elects Magnus Nylén as New Member of Board	22-11-24	CI
Selectimmune Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-16	CI
Selectimmune Pharma Has Successfully Completed Preparations to Start A Controlled Clinical Trial in Patients with Bladder Pain Syndrome	22-11-14	CI
Selectimmune Pharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	22-08-30	CI
Selectimmune Pharma AB Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI
Selectimmune Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-24	CI
Selectimmune Pharma AB Appoints Gabriela Godaly as Acting CEO	22-04-26	CI
Selectimmune Pharma AB Receives Approval to Conduct A Placebo-Controlled Clinical Study of Bladder Pain	22-04-25	CI
Selectimmune Pharma AB to Conduct Clinical Trials in Cystitis and Bladder Pain Syndrome	22-03-29	CI
Selectimmune Pharma AB Announces Resignation of Ann Gidner as CEO	22-03-27	CI
Selectimmune Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-24	CI
SelectImmune Pharma AB Files Important Patent Application for Acute Pyelonephritis	22-02-01	CI
Selectimmune Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-18	CI
Selectimmune Pharma AB Publ Reports Earnings Results for the Fourth Quarter Ended June 30, 2021	21-08-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Selectimmune Pharma AB (publ)

Equities

SELECT B

SE0012622785

Summary

Filters